

# Cluster-randomized trials

## Including cluster-crossover designs

Sven Trelle

*u*<sup>b</sup>


---

b  
UNIVERSITÄT  
BERN



# Cluster-randomized trials

An old design experiences a revival ...



**Registration is Open!**  
\*please click on download pictures to view all information

To get more information  
and to register, please  
click [here](#)

**Cluster Randomized Clinical  
Trials (CRTs): Opportunities  
and Challenges**

**April 29, 2020  
(7:30 Breakfast - 4:30pm)**

13th Annual Conference on  
Statistical Issues in Clinical Trials  
Rubenstein Auditorium  
UPenn School of Medicine  
Philadelphia, PA 19104

DEPARTMENT of  
**BIostatISTICS  
EPIDEMIOLOGY &  
INFORMATICS**

METHODS
David Murray, PhD (NIH)
Overview: <i>Innovations in the Design and Analysis of Group- or Cluster- Randomized Trials</i>
Victor DeGruttola, ScD (Harvard)
<i>Using Network- and Individual-Level Information in Design and Analysis of Clustered Trials</i>
Luke J. Keele, PhD (University of Pennsylvania)
<i>Complexities Caused by Noncompliance in Cluster Randomized Trials</i>
James P. Hughes, PhD (University of Washington)
<i>Current Issues in the Design and Analysis of Stepped Wedge Trials</i>
APPLICATIONS
Lawrence H. Moulton, PhD (Johns Hopkins University)
Randomization: Beyond the Clorization Principle
Ira Longini, PhD (University of Florida)
<i>The Ring Vaccine Trial Design for the Estimation of Vaccine Efficacy and Effectiveness During Infectious Disease Outbreaks</i>
Deborah J. Donnell, PhD (University of Washington)
<i>Challenges in Implementing CRTs: From Hawthorne Effect to Measurement Bias</i>
Weili He, PhD (AbbVie)
<i>Practical Considerations in Utilizing Cluster Randomized Trials in Medical Research</i>
PANEL DISCUSSIONS
Karla Hemming, PhD (University of Birmingham)
David Murray, PhD (National Institutes of Health)
Michael Proschan, PhD (National Institutes of Health)
Jeffrey Roberts, MD (US Food and Drug Administration)
Alisa Shields-Stephens, PhD (University of Pennsylvania)
Monica Taljaard, PhD (Ottawa Hospital Research Institute)

1. Cluster-randomized trials
  - a. Definition
  - b. Applications and examples
  - c. Main advantages/rationale
  - d. Main pitfalls and disadvantages
  - e. Sample size and analysis
2. Cluster cross-over trials
3. A note on the stepped wedge design
4. Ethical aspects and informed consent

Note: This presentation is only a teaser, as all the others in this course ...

# The key message

## As starter

Generally speaking:

Only do a cluster trial if absolutely necessary – otherwise do an individually randomized-controlled trial

→ Cluster design requires good justification



## Cluster-randomized trial

- The unit of outcome measurement/analysis is nested within the unit of randomization (and therefore different)
  - All units within a cluster receive the same intervention but clusters are randomly allocated to an intervention
- Some relation to hierarchical/multi-level modelling
- Other forms of clustering in health research (which have no direct relation to cluster trials):
  - Center-effects in multicenter trials
  - Therapist (e.g. surgeon) effects in trials of non-drug (complex) interventions
  - ...

# Types of clusters

## Examples from practice

- Wards
- (General) practices
- Hospitals
- Physicians/health-care providers
- Geographical regions
- Not necessarily «health service research» → patients as clusters
  - Teeth
  - Joints
  - Eyes
  - ...

# Types of interventions

## Some examples

- Very often
    - Educational interventions
    - Complex interventions in general
    - Expensive machines
    - Health policy/service interventions (e.g. insurance models)
  - More rarely (at least in the past)
    - Pharmaceutical products
    - Medical devices
- i.e. classical health-care interventions

# Clustering and the intervention


## Sometimes causing confusion

- The unit of randomization is not **necessarily** the unit at which the intervention is applied i.e. the cluster unit might not be the direct recipient of the intervention

# Intervention administered at cluster and nested level

## Clustering and the intervention


- The unit of randomization is not **necessarily** the unit at which the intervention is applied i.e. the direct recipient of the intervention



# Intervention administered at cluster level

## Clustering and the intervention


- The unit of randomization is not **necessarily** the unit at which the intervention is applied i.e. the direct recipient of the intervention



# Intervention administered at nested level

## Clustering and the intervention

- The unit of randomization is not **necessarily** the unit at which the intervention is applied i.e. the direct recipient of the intervention



# Applications and examples

*u*<sup>b</sup>


---

<sup>b</sup>  
UNIVERSITÄT  
BERN



# Antibiotic stewardship as a classical type of trial

Gerber JS et al. 2013




# Antibiotic stewardship as a classical type of trial

Gerber JS et al. 2013

- Intervention
    - On-site education session
    - Personalized, quarterly audit and prescription feedback (1 year)
  - Control
    - Standard of care i.e. no education, no audit or feedback
  - Main outcome
    - Broad-spectrum (off-guideline) antibiotic prescription (per patient)
- Intervention administered at cluster-level i.e. indirect effect measured

# Public health intervention (vaccination)


## Ebola çauffit!



# Ebola ça suffit!

## Rationale for cluster design

- Cluster design not uncommon in vaccine trials (usually geographically defined)
  - Also driven by feasibility
- Intervention administered at nested level i.e. direct effect measured



*Ebola ça Suffit Ring Vaccination Trial Consortium 2015*


## Specific design features


- A cluster factorial randomised controlled trial comparing
  - oral hygiene advice and(/or) periodontal instrumentation
  - with routine care
  - for the prevention and management of periodontal disease
  - in adults
- Almost all design features of individually randomized trials can be applied to cluster trials e.g. stratification, matched-pairs randomization, factorial, cross-over designs (later in talk)

# Matched pairs randomization

## Mexican universal health insurance programme trial

- To evaluate aspects of Seguro Popular, a program with
  - health insurance,
  - regular and preventive medical care,
  - medicines, and
  - health facilitiesto 50 million uninsured Mexicans.
- Clusters: 148 **health facility catchment areas** (74 matched pairs)
- Nested units: households
- Outcome (1<sup>st</sup>): **catastrophic (health) expenditures**





# Households as cluster units

## Home Injury Prevention Intervention (HIPI)

- Assessor-blind, cluster-randomised controlled trial of 842 **households** comparing
- immediate home modifications (treatment group)
- with 3-year wait before modifications (control group)
- for **falls** at home that needed medical treatment.

# Individuals as cluster unit

Watthanasaen S et al. 2017

- This cluster randomised controlled trial evaluated
- a school-based xylitol chewing-gum programme
- on caries onset rate measured as the change in caries onset on **tooth** surfaces
- among 174 **students** with visual or hearing impairment.




# Advantages and rationale for design choice

*u*<sup>b</sup>

---

b  
UNIVERSITÄT  
BERN



1.c.

# Type of intervention

## As a driver for cluster design

- Intervention can only be applied at cluster level but (main) outcome of interest is on nested level
  - Examples
    - Smoking bans
    - Insurance models
    - ...
- Implicitly, the underlying reason is actually contamination

# Type of intervention

## Really a cluster trial?

- Just because an intervention is applied at a ‘clustering’ units does not make a trial (necessarily) a cluster trial
- It needs to satisfy also the second condition: outcome measured at nested units
- Can sometimes be difficult to see especially with binary outcomes (flag: only cluster-level analyses planned)
  - But sometimes also tricky the other way round: an individual randomized trial that is actually a cluster trial ...
- Depends on the research question
- Antibiotic stewardship trial as example
  - Alternatives: overall costs for antibiotics, antibiotic prescriptions per practice, ...

# Contamination

## Main rationale for design

- Individuals (nested units) randomized to one intervention exposed to the comparison intervention
- Either experimental OR control i.e. contamination can be in both directions
- When defining the cluster unit, carefully check mechanism of contamination
- Some contamination is acceptable (see Hewitt CE et al. 2008)



# Other arguments

## Broad forward

- Logistical convenience
- Reduced costs
- More pragmatic
- Consent easier (sometimes not needed at all)


# Pitfalls and disadvantages



1.d.

# Selection bias

## The major methodological challenge



# Selection bias


## Two types of mechanisms

- Foreknowledge of allocation leads to
  - selective enrollment (Schulz K et al. 1994, Jordhoy MS et al. 2002)
  - selective participation
    - by not showing up at the cluster unit at all
    - differential consent (Molloy DW et al. 2000)

# Selection bias

## Empirical data


- Trials evaluating hip protectors for prevention of hip fractures



# Sidenote: baseline imbalance


## In cluster trials

- Selection bias or random chance
- More frequent in cluster trials than in individually randomized trials



# Selection bias

Allocation in batches to achieve concealment of allocation



# Sample size and analysis



## General comments

- Power is affected by the (statistical) correlation of nested units within clusters i.e. observations within the same cluster tend to vary less than randomly selected observations from the overall population
- Correlation is quantified by the Intraclass/-cluster Correlation Coefficient (ICC)
- Fixing the intraclass correlation coefficient for sample size calculation most challenging (often unknown)
- Estimates of intraclass correlation coefficients from studies < ca. 40 cluster units highly uncertain, even more pronounced for binary outcomes (Ukoumunne OC 2004)

# Sample size

## Design factor

- Typical intraclass correlation coefficients range from 0.01 to 0.05 but might go up to 0.1 and can be considerably larger than anticipated (e.g.  $ICC_{\text{assumed}} 0.022 \rightarrow ICC_{\text{observed}} 0.11$  (Vitiello MV et al. 2013))
- This, and the large uncertainty in estimates  $\rightarrow$  be conservative i.e. round up rather down
- Calculate sample size for an individually randomized trial and inflate by variance inflation (design) factor
- Formula:  $VIF = 1 + (m - 1)\rho$ 
  - $VIF$ , Variance Inflation Factor (design factor)
  - $m$ , (weighted) average cluster size, check formula (extension: allowance for variable cluster size)
  - $\rho$ , intraclass correlation coefficient

# Sample size


## Design factor

- Typical intraclass correlation coefficient might go up to 0.1 and can be estimated (e.g.  $ICC_{\text{assumed}} = 0.022 \rightarrow ICC_{\text{observed}}$ )
- This, and the large uncertainty, round up rather than down
- Inflate sample size for an individual

– **Formula:  $VIF = 1 + (m - 1)\rho$**

$VIF$ , Variance Inflation Factor (design factor)  
 $m$ , (weighted) average cluster size, cluster size

$\rho$ , intraclass correlation coefficient




## See references

- Usually individual- AND cluster-level outcome data
- Think about baseline adjustment (also characteristics of nested units)
- Clustering must be taken into account (otherwise (highly) anti-conservative i.e. type I error inflated)
- May allow for changes over time of intracluster correlation (Grantham KL et al. 2019)
- Main choices for individual-level analysis
  - Standard regression models with robust standard errors
  - Generalized Estimating Equations (GEE) with ‘exchangeable’ correlation matrix with robust standard errors (< ca. 80-90 clusters, Kahan BC et al. 2016)
  - Random (mixed) effects regression
- Difference between random-effects and population-averaged estimators → <https://www.stata.com/support/faqs/statistics/random-effects-versus-population-averaged/>

# Take home messages

- Stick to individually randomized designs if possible
- Identify the cluster and nested unit
- Take all (statistical) correlations into account in the design and analysis
- Analyses can easily get very complex



# Thank you for your attention!

Sven Trelle

## References

- Anderson CS et al. 2017. N Engl J Med; 376: 237-47.
- Arnup SJ et al. 2016. J Clin Epidemiol; 74: 40-50.
- Crespi CM 2016. Ann Rev Public Health; 37: 1-16.
- Donner A, Klar N 2004. Am J Public Health; 94: 416-22.
- Ebola ça Suffit Ring Vaccination Trial Consortium 2015. BMJ; 351: h3740.
- Gantham KL et al. 2019. Stat Med; 38: 5021-33.
- Gerber JS et al. 2013. JAMA; 309: 2345-52.
- Goldstein CE et al. 2018. Can J Anesth; 65: 760-5.
- Grantham KL et al. 2019. Stat Med; 38: 1918-34.
- Grayling MJ et al. 2017. Trials; 18: 33.
- Grayling MJ et al. 2019. Stat Med; 38: 1103-19.
- Han S et al. 2005. BMC Med Res Methodol; 5: 10.
- Hemming K et al. 2014. Stat Med; 34: 181-96.
- Hemming K et al. 2015. BMJ; 35: h391.
- Hewitt CE et al. 2008. J Clin Epidemiol; 61: 1004-8.
- Hooper R and Copas A 2019. J Clin Epidemiol; 116: 161-6.
- Jordhoy MS et al. 2002. Palliative Med; 16: 43-9.
- Kahan BC et al. 2016. Trials; 17: 438.
- Keall MD et al. 2015. Lancet; 385: 231-8.

Cont'



# References

## Cont'

- Kelly T-L and Pratt N 2019. Stat Med; Epub ahead of print.
- King G et al. 2009. Lancet; 373: 1447-54.
- Lignou S 2018. J Med Ethics; 44: 114-20.
- Ma J et al. 2013. BMC Med Res Methodolo; 13: 9.
- Molloy DW et al. 2000. JAMA; 283: 1437-44.
- Peters TJ et al. 2003. Int J Epidemiol; 32: 840-6.
- Ramsay CR et al. 2018. Health Technol Assess; 22: 1-144.
- Schulz K et al.1994. JAMA; 272: 125-8.
- Solomon E et al. 2014. Int J Behav Nutr Phys Act; 11: 94.
- Turner RM et al. 2007. Stat Med; 26: 274-89.
- Ukoumunne OC 2004. Stat Med; 21: 3757-74.
- Van der Graaf et al. 2015. J Clin Epidemiol; 68: 1108-14.
- Viechtbauer W et al. 2014. J Clin Epidemiol; 67: 834-6.
- Vitiello MV et al. 2013. J Am Geriatr Soc 61:947–56.
- Watthanasaen S et al. 2017. Oral Health Prev Dent; 15: 519-27.
- Weijer C et al. 2012. PLoS Med 9: e1001346.
- Weijer C and Taljaard M 2019. J Clin Epidemiol; 116: 140-5.
- Yang S et al.2020. Contemp Clin Trials; 88: 105775.

### Photos

- Desire from johnhain at pixabay
- Sport from Rilsonav at pixaby
- Icons by Streamline

